This market analysis by Technavio segments the global psoriatic arthritis market by mechanism of action (TNF inhibitors, PDE4 inhibitors, interleukin blockers, and others), by type of molecule (biologics and small molecules), by type of disease (mild psoriatic arthritis, moderate psoriatic arthritis, and severe psoriatic arthritis), by route of administration (oral, parenteral, and topical), by dosage form (solid, liquid, and semi-solid), and by geography (Americas, EMEA, and APAC). Key vendors in this market are Abbvie, Amgen, Janssen Pharmaceuticals, Celgene, and UCB.
Technavio’s market research analysts estimate the global psoriatic arthritis market to grow at a CAGR of around 5% between 2015 and 2019. Factors that can be attributed to this market’s growth are the increase in penetration of biologic therapies and recent launch of products like Otezla and Stelara. The Americas dominate the global market for psoriatic arthritis therapeutics, accounting for 52% of the overall market share. The higher intake of existing biologic drugs for psoriatic arthritis treatment, the launch of new biologics, and expanded access to medical care as a result of healthcare reforms are driving the psoriatic arthritis therapeutics market in the Americas.
The new market research report from Technavio provides a breakdown and analysis of the psoriatic arthritis segments by technology.
“The launch of biosimilars to detect psoriatic arthritis is an important development in this market. Unlike generic drugs, biosimilars have identical active pharmaceutical ingredients, which are almost similar to their originator biologic compounds. These drugs are less expensive than biologics, and hence are more accessible to the patients. The expiry patents of the existing biologic drugs has led to the emergence of biosimilars. Inflectra is a biosimilar of Remicade while GP2015 is a biosimilar of Enbrel,” says Imran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research.
The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.
The key vendors in the global psoriatic arthritis market include Abbvie, Amgen, Janssen Pharmaceuticals, Celgene and UCB. This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.
A more detailed analysis is available in the Technavio report, Global Psoriatic Arthritis Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other related reports:
